Background
Methods
Study cohort and the population of interest
Allopurinol treatment definition
Study covariates and potential confounders
Study outcome
Statistical analyses
Results
Clinical and demographic characteristics
All new allopurinol use episodes | Allopurinol new use episodesa associated with versus without ventricular arrhythmias (VA) during the follow-up |
P value | ||
---|---|---|---|---|
VA | No VA | |||
Total, N (episodes)
|
28,755
|
2538
|
26,217
| |
Age, mean (SD) | 76.6 (7.4) | 77.2 (7.3) | 76.5 (7.5) |
< 0.0001
|
Sex, N (%) |
< 0.0001
| |||
Male | 14,074 (48.9%) | 1369 (53.9%) | 12,705 (48.5%) | |
Female | 14,681 (51.1%) | 1169 (46.1%) | 13,512 (51.5%) | |
Race/Ethnicity, N (%) |
< 0.0001
| |||
White | 22,693 (78.9%) | 1976 (77.9%) | 20,717 (79.0%) | |
Black | 3510 (12.2%) | 382 (15.1%) | 3128 (11.9%) | |
Hispanic | 606 (2.1%) | 49 (1.9%) | 557 (2.1%) | |
Asian | 1268 (4.4%) | 89 (3.5%) | 1179 (4.5%) | |
Native American | 97 (0.3%) | 7 (0.3%) | 90 (0.3%) | |
Other/unknown | 581 (2.0%) | 35 (1.4%) | 546 (2.1%) | |
Region, N (%) |
0.03
| |||
Northeast | 4607 (16.0%) | 460 (18.1%) | 4147 (15.8%) | |
Midwest | 7315 (25.4%) | 626 (24.7%) | 6689 (25.5%) | |
South | 11,563 (40.2%) | 1003 (39.5%) | 10,560 (40.3%) | |
West | 5270 (18.3%) | 449 (8.5%) | 4821 (18.4%) | |
Charlson–Romano comorbidity score | 3.65 (3.25) | 4.79 (3.40) | 3.54 (3.21) |
< 0.0001
|
Association of allopurinol use with ventricular arrhythmias
Univariate | Multivariable adjusted (Model 1) | Multivariable adjusted (Model 2) | ||||
---|---|---|---|---|---|---|
HR (95% CI) |
P value | HR (95% CI) |
P value | HR (95% CI) |
P value | |
Age (in years) | ||||||
65 to < 75 | Ref | Ref | Ref | |||
75 to < 85 |
1.25 (1.15–1.36)
|
< 0.0001
|
1.19 (1.09–1.30)
|
< 0.0001
|
1.19 (1.09–1.30)
|
< 0.0001
|
≥ 85 |
1.43 (1.28–1.60)
|
< 0.0001
|
1.37 (1.22–1.53)
|
< 0.0001
|
1.37 (1.22–1.53)
|
< 0.0001
|
Sex | ||||||
Male | Ref | Ref | Ref | |||
Female | 0.81 (0.75–0.87) | 0.50 |
0.74 (0.68–0.80)
|
< 0.0001
|
0.73 (0.68–0.80)
|
< 0.0001
|
Race | ||||||
White | Ref | Ref | Ref | |||
Black |
1.32 (1.19–1.48)
|
< 0.0001
|
1.30 (1.16–1.45)
|
< 0.0001
|
1.29 (1.15–1.44)
|
< 0.0001
|
Other |
0.80 (0.69–0.94)
|
0.005
|
0.78 (0.67–0.91)
|
0.002
|
0.78 (0.67–0.90)
|
0.001
|
Charlson–Romano score, per unit change |
1.15 (1.14–1.16)
|
< 0.0001
|
1.14 (1.13–1.16)
|
< 0.0001
|
1.14 (1.13–1.16)
|
< 0.0001
|
Diuretics | 1.12 (0.94–1.33) | 0.21 | 1.03 (0.86–1.24) | 0.72 | 1.03 (0.86–1.24) | 0.74 |
Statins | 0.86 (0.70–1.05) | 0.13 |
0.79 (0.64–0.97)
|
0.02
|
0.79 (0.64–0.97)
|
0.02
|
ACE inhibitor | 1.09 (0.88–1.34) | 0.43 | 1.11 (0.90–1.38) | 0.32 | 1.11 (0.90–1.38) | 0.33 |
Beta blockers |
1.42 (1.20–1.68)
|
< 0.0001
|
1.41 (1.18–1.68)
|
0.0001
|
1.40 (1.18–1.68)
|
0.0001
|
Allopurinol use |
0.86 (0.79–0.94)
|
0.001
|
0.82 (0.76–0.90)
|
< 0.0001
| – | – |
Allopurinol use durationa
| ||||||
0 days | Ref | – | – | Ref | ||
1 to 180 days | 0.99 (0.88–1.12) | 0.88 | – | – | 0.96 (0.85–1.08) | 0.49 |
181 days to 2 years |
0.81 (0.72–0.90)
|
0.0002
| – | – |
0.76 (0.68–0.85)
|
< 0.0001
|
> 2 years |
0.74 (0.62–0.90)
|
0.002
| – | – |
0.72 (0.60–0.87)
|
0.001
|
Multivariable adjusted (Model 3) | Multivariable adjusted (Model 4) | |||
---|---|---|---|---|
HR (95% CI) |
P value | HR (95% CI) |
P value | |
Allopurinol use |
0.82 (0.75–0.89)
|
< 0.0001
| – | – |
Allopurinol use durationa
| ||||
0 days (non-use) | – | – | Ref | |
1–180 days | – | – | 0.92 (0.82–1.04) | 0.18 |
181 days to 2 years | – | – |
0.76 (0.68–0.84)
|
< 0.0001
|
> 2 years | – | – |
0.78 (0.65–0.94)
|
0.009
|
Exploratory subgroup analyses by VA risk factors, previous MI, race/sex, and for VF
Allopurinol use (using model 5) HR (95% CI) [P value] | Allopurinol use duration (using model 6) HR (95% CI) [P value] | |||||
---|---|---|---|---|---|---|
No | Yes | 0 day | 1 to 180 days | 181 days to 2 years | > 2 years | |
Coronary artery disease | ||||||
No | 1 |
0.60 (0.47–0.78) [0.0001]
| Ref | 0.71 (0.47–1.06) [0.09] |
0.57 (0.42–0.83) [0.002]
|
0.45 (0.25–0.81) [0.007]
|
Yes | Ref |
0.85 (0.77–0.95) [0.003]
| Ref | 0.97 (0.84–1.12) [0.64] |
0.79 (0.69–0.90) [0.001]
|
0.79 (0.62–0.99) [0.04]
|
Cardiomyopathy-dilated or hypertrophic | ||||||
No | Ref |
0.80 (0.71–0.90) [0.0002]
| Ref | 0.91 (0.77–1.07) [0.26] |
0.75 (0.65–0.88) [0.0002]
|
0.71 (0.55–0.91) [0.007]
|
Yes | Ref |
0.84 (0.71–0.99) [0.04]
| Ref | 0.95 (0.75–1.21) [0.68] |
0.77 (0.62–0.96) [0.02]
| 0.73 (0.46–1.15) [0.17] |
Heart failure | ||||||
No | Ref |
0.74 (0.65–0.85) [< 0.0001]
| Ref | 0.88 (0.73–1.07) [0.20] |
0.67 (0.55–0.81) [< 0.0001]
|
0.66 (0.50–0.89) [0.006]
|
Yes | Ref | 0.89 (0.78–1.01) [0.08] | Ref | 0.98 (0.81–1.18) [0.82] |
0.84 (0.74–0.99) [0.04]
| 0.79 (0.57–1.10) [0.16] |
Congenital heart disease | ||||||
No | Ref |
0.82 (0.74–0.90) [< 0.0001]
| Ref | 0.93 (0.81–1.06) [0.26] |
0.76 (0.68–0.87) [< 0.0001]
|
0.73 (0.59–0.91) [0.005]
|
Yes | Ref | 0.80 (0.41–1.57) [0.52] | Ref | 1.36 (0.60–3.11) [0.47] | 0.52 (0.18–1.44) [0.21] |
0.00 (0.0–0.0) [< 0.0001]
|
Valvular heart disease | ||||||
No | Ref |
0.82 (0.74–0.92) [0.0004]
| Ref | 0.94 (0.81–1.09) [0.39] |
0.77 (0.67–0.88) [0.0002]
|
0.74 (0.58–0.94) [0.01]
|
Yes | Ref |
0.78 (0.63–0.97) [0.025]
| Ref | 0.92 (0.68–1.24) [0.56] |
0.72 (0.58–0.95) [0.018]
| 0.66 (0.38–1.13) [0.13] |
Renal failure | ||||||
No | Ref |
0.81 (0.67–0.98) [0.03]
| Ref | 0.93 (0.70–1.24) [0.62] | 0.79 (0.62–1.01) [0.06] | 0.63 (0.42–0.96) [0.03] |
Yes | Ref |
0.81 (0.73–0.91) [0.0003]
| Ref | 0.93 (0.80–1.09) [0.37] |
0.75 (0.65–0.86) [< 0.0001]
|
0.75 (0.58–0.97) [0.03]
|
Dialysis | ||||||
No | Ref |
0.81 (0.73–0.89) [< 0.0001]
| Ref | 0.90 (0.79–1.03) [0.14] |
0.76 (0.67–0.87) [< 0.0001]
|
0.73 (0.53–0.90) [0.004]
|
Yes | Ref | 1.36 (0.54–3.43) [0.52] | Ref |
2.43 (1.03–5.69) [0.04]
| 0.73 (0.19–2.77) [0.64] |
0.00 (0.0–0.0) [< 0.0001]
|
Sarcoidosis | ||||||
No | Ref |
0.81 (0.74–0.89) [< 0.0001]
| Ref | 0.93 (0.81–1.06) [0.29] |
0.76 (0.67–0.85) [< 0.0001]
|
0.72 (0.58–0.90) [0.003]
|
Yes | Ref | 0.86 (0.13–5.58) [0.88] | Ref | 0.73 (0.05–11.2) [0.82] | 1.11 (0.11–11.41) [0.93] |
0.00 (0.0–0.0) [< 0.0001]
|
Hyperkalemia | ||||||
No | Ref |
0.81 (0.73–0.91) [0.0002]
| Ref | 0.92 (0.78–1.08) [0.31] |
0.76 (0.66–0.88) [0.0001]
|
0.73 (0.57–0.93) [0.01]
|
Yes | Ref |
0.82 (0.68–0.99) [0.04]
| Ref | 0.95 (0.73–1.22) [0.68] |
0.76 (0.59–0.97) [0.03]
| 0.67 (0.42–1.08) [0.10] |